Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes

American Journal of Hematology

Volumn 91, Issue 10, 2016, Pages 989-994

  Habibi, Anoosha ^a,b   Mekontso Dessap, Armand ^c,d   Guillaud, Constance ^a   Michel, Marc ^a   Razazi, Keyvan ^c   Khellaf, Mehdi ^a,b   Chami, Btissam ^e   Bachir, Dora ^a   Rieux, Claire ^a   Melica, Giovanna ^a   Godeau, Bertrand ^a   Galacteros, Frédéric ^a,b   Bartolucci, Pablo ^a,b   Pirenne, France ^b,e  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB;

ACUTE CHEST SYNDROME; ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD TRANSFUSION REACTION; BLOOD VESSEL OCCLUSION; BLOOD VESSEL REACTIVITY; CLINICAL FEATURE; DELAYED HEMOLYTIC TRANSFUSION REACTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBINURIA; HUMAN; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; INTRAVASCULAR HEMOLYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; TREATMENT OUTCOME; URINE COLOR;

EID: 84990247298     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24460     Document Type: Article

References (28)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5–11.
2. Cohen AR, Martin MB, Silber JH, et al. A modified transfusion program for prevention of stroke in sickle cell. Blood 1992;79:1657–1661.
3. Driss F, Tertian G, Becquemont L, et al. Prise en charge des grossesses à risque chez les femmes drépanocytaires: intérêt d'une stratégie préventive par des transfusions de globules rouges ou des échanges érythrocytaires automatisés. Transfus Clin Biol 2007;14:386–392.
4. Oteng-Ntim E, Chase AR, Howard J, Khazaezadeh N, Anionwu EN. Sickle cell disease in pregnancy. Obstet Gynaecol Reprod Med 2008;18:272–278.
5. Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012;26:25–36.
6. Kokoska ER, West KW, Carney DE, et al. Risk factors for acute chest syndrome in children with sickle cell disease undergoing abdominal surgery. J Pediatr Surg 2004;39:848–850.
7. Ngô C, Kayem G, Habibi A, et al. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynecol Reprod Biol 2010;152:138–142.
8. Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 2015;169:746–753.
9. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008;48:1231–1238.
10. de Montalembert M, Dumont M-D, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011;96:801–807.
11. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol 2015;170:745–56.
12. King KE, Shirey RS, Lankiewicz MW, et al. Transfusion delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. 1997;37:376–381.
13. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120:528–537.
14. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016;127:1062–1064.
15. Lionnet F, Arlet J-B, Bartolucci P, et al. Recommandations pratiques de prise en charge de la drépanocytose de l'adulte. Rev Méd Interne 2009;30:S162–S223.
16. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death: suicidal RBC death as a mechanism of DHTR in SCD. Transfusion (Paris) 2009;49:1785–1792.
17. Noizat-Pirenne F, Habibi A, Mekontso-Dessap A, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang 2015;108:262–267.
18. Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood 2009;114:3742–3747.
19. Kato G, Gladwin M, Steinberg M. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37–47.
20. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015;168:291–300.
21. Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998;92:3082–3089.
22. Win N, Sinha S, Lee E, Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 2010;24:64–67.
23. Bachmeyer C, Maury J, Parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010;85:91–92.
24. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007;92:e132–e135.
25. Hayes C, Shafi H, Mason H, Klapper E. Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report. Transfus Apher Sci 2015;54:253–255.
26. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333:206–214.
27. Habibi A, Arlet J-B, Stankovic K, et al. Bartolucci P. recommandations françaises de prise en charge de la drépanocytose de l'adulte: actualisation 2015. Rev Méd Interne 2015;36:5S3–5S84.
28. Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 1988;319:1447–1452.